---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-002587"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:29:53.203898+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics receives FDA IND clearance for BDTX-1535; Phase 1 start in Q1 2022

## Summary
- FDA allowed IND application for BDTX-1535 on January 10, 2022.
- Phase 1 study of BDTX-1535 to begin in Q1 2022.
- Company expects to provide a clinical update in the second half of 2023.

## SEC filing metadata
- accession: 0001104659-22-002587
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465922002587/0001104659-22-002587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465922002587/tm222372d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-002587
- JSON: https://secwatch.observer/filing/0001104659-22-002587.json
- Plain text: https://secwatch.observer/filing/0001104659-22-002587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.